Navigation Links
Helix BioPharma announces Q1 2008 financial results
Date:12/17/2007

---------------------------

12,610 14,273

---------------------------

---------------------------

Current liabilities:

Accounts payable 735 565

Accrued liabilities 609 974

---------------------------

1,344 1,539

Shareholders' equity 11,266 12,734

---------------------------

12,610 14,273

---------------------------

---------------------------

-------------------------------------------------------------------------

The Company's unaudited interim consolidated financial statements and management's discussion and analysis of financial condition and results of operations have been filed, today, with Canadian securities regulatory authorities and will be available at SEDAR at http://www.sedar.com.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not acce
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
11. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website ... are used solely in scientific experiments, is currently celebrating ... in business, Maxim Peptide, which was created by the ... new and updated website that now features a special ... been updated with fascinating articles about peptide research, including ...
(Date:7/11/2014)... 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) ... (eslicarbazepine acetate) for use as a once-daily adjunctive therapy ... epilepsy who are not satisfactorily controlled with conventional therapy. ... patients under 18 years of age. ... and according to Epilepsy Canada, it affects 0.6% of ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... DIEGO, Dec. 15, 2010 Ocera Therapeutics, Inc. ... evaluating the safety and pharmacokinetics of OCR-002 (ornithine ... liver cirrhosis.  OCR-002 recently received Orphan Drug status ... Food and Drug Administration for the treatment of ...
... , This release is available in ... scientists have identified the primary site where the virus ... This discovery could lead to development of new ... contagious and sometimes fatal viral disease of cloven-hoofed animals ...
... small cabinet the size of a dorm refrigerator in one of ... bottles under the cool light of red, blue and green LEDS. ... of champions. The soup is colored by a strain of ... produced by their nearest competitorsin part because of their unique genetic ...
Cached Biology Technology:Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 2Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 3USDA scientists discover how foot-and-mouth disease virus begins infection in cattle 2Champion hydrogen-producing microbe 2Champion hydrogen-producing microbe 3Champion hydrogen-producing microbe 4
(Date:7/11/2014)... University of Chicago is creating a new professorship ... the University,s Institute for Molecular Engineering and the ... donation from the Millicent and Eugene Bell Foundation., ... reside within the Institute for Molecular Engineering. That ... project at the MBL,s Eugene Bell Center for ...
(Date:7/11/2014)... "mouse TRAP" to capture the early signs of kidney ... the Journal of Clinical Investigation . Their new ... extract cellular and genetic information from a variety of ... Institute for Medical Research in 2008, TRAP involves attaching ... of the cell type of interest. Scientists can then ...
(Date:7/11/2014)... 10, 2014---A team of researchers from The Chinese University ... a gene of wild soybean linked to salt tolerance, ... in saline soil. This study published online in ... novel genomic information for crop improvement. , Soybean is ... and human selection, cultivated soybeans have less genetic diversities ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... Richfield Co. was tasked with cleaning up a major superfund ... Texas A&M University professor, got a call to assist the ... crop science professor, spent two years leading a Texas A&M ... of copper mining, mineral processing and smelting in the Anaconda, ...
... In the first side-by-side tests of a half-dozen palladium- and ... scientists have found that palladium destroys TCE far faster than ... cases. The results will appear in a new study ... B: Environmental. TCE, or trichloroethene, is a widely ...
... 2012: Element Six, the world leader in synthetic ... of Warwick,s Departments of Chemistry and Physics, have ... properties of metal-like boron-doped synthetic diamond. The research ... properties while retaining the full strength and durability ...
Cached Biology News:Mining cleanup benefits from Texas A&M expertise 2Mining cleanup benefits from Texas A&M expertise 3Palladium-gold nanoparticles clean TCE a billion times faster than iron filings 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 3
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
... M. Walker (1996) • This book ... for studying proteins and peptides. Each ... step-by-step instruction, timesaving troubleshooting tips, alternative ... of reagents and suppliers. Topics covered ...
...
Biology Products: